Increased Lysosomal Exocytosis Induced by Lysosomal Ca Channel Agonists Protects Human Dopaminergic Neurons from α-Synuclein Toxicity
Overview
Authors
Affiliations
The accumulation of misfolded proteins is a common pathological feature of many neurodegenerative disorders, including synucleinopathies such as Parkinson's disease (PD), which is characterized by the presence of α-synuclein (α-syn)-containing Lewy bodies. However, although recent studies have investigated α-syn accumulation and propagation in neurons, the molecular mechanisms underlying α-syn transmission have been largely unexplored. Here, we examined a monogenic form of synucleinopathy caused by loss-of-function mutations in lysosomal ATP13A2/PARK9. These studies revealed that lysosomal exocytosis regulates intracellular levels of α-syn in human neurons. Loss of PARK9 function in patient-derived dopaminergic neurons disrupted lysosomal Ca homeostasis, reduced lysosomal Ca storage, increased cytosolic Ca, and impaired lysosomal exocytosis. Importantly, this dysfunction in lysosomal exocytosis impaired α-syn secretion from both axons and soma, promoting α-syn accumulation. However, activation of the lysosomal Ca channel transient receptor potential mucolipin 1 (TRPML1) was sufficient to upregulate lysosomal exocytosis, rescue defective α-syn secretion, and prevent α-syn accumulation. Together, these results suggest that intracellular α-syn levels are regulated by lysosomal exocytosis in human dopaminergic neurons and may represent a potential therapeutic target for PD and other synucleinopathies. Parkinson's disease (PD) is the second most common neurodegenerative disease linked to the accumulation of α-synuclein (α-syn) in patient neurons. However, it is unclear what the mechanism might be. Here, we demonstrate a novel role for lysosomal exocytosis in clearing intracellular α-syn and show that impairment of this pathway by mutations in the PD-linked gene ATP13A2/PARK9 contributes to α-syn accumulation in human dopaminergic neurons. Importantly, upregulating lysosomal exocytosis by increasing lysosomal Ca levels was sufficient to rescue defective α-syn secretion and accumulation in patient neurons. These studies identify lysosomal exocytosis as a potential therapeutic target in diseases characterized by the accumulation of α-syn, including PD.
Mesentier-Louro L, Goldman C, Ndayisaba A, Buonfiglioli A, Rooklin R, Schuldt B bioRxiv. 2025; .
PMID: 39975381 PMC: 11839026. DOI: 10.1101/2025.02.09.637107.
Canonical and noncanonical autophagy: involvement in Parkinson's disease.
Sakurai M, Kuwahara T Front Cell Dev Biol. 2025; 13:1518991.
PMID: 39949604 PMC: 11821624. DOI: 10.3389/fcell.2025.1518991.
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases.
Chen L, Shen Q, Liu Y, Zhang Y, Sun L, Ma X Signal Transduct Target Ther. 2025; 10(1):31.
PMID: 39894843 PMC: 11788444. DOI: 10.1038/s41392-024-02071-0.
Tsunemi T, Ishiguro Y, Yoroisaka A, Feng D, Shimada T, Niiyama S J Neurosci. 2025; 45(11).
PMID: 39794126 PMC: 11905360. DOI: 10.1523/JNEUROSCI.2350-23.2024.
Carbonic anhydrase inhibition ameliorates tau toxicity via enhanced tau secretion.
Lopez A, Siddiqi F, Villeneuve J, Ureshino R, Jeon H, Koulousakis P Nat Chem Biol. 2024; .
PMID: 39482469 DOI: 10.1038/s41589-024-01762-7.